We are live on
!
Find out more
KCA
KVP Capital Advisors Portfolio holdings
AUM
$136M
This Fund
S&P 500
This Quarter
Est. Return
+167.4%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$103M
AUM Growth
–
Cap. Flow
+$78.5M
Cap. Flow
% of AUM
76.01%
Top 10 Holdings %
Top 10 Hldgs %
68.49%
Holding
27
New
27
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$10.2M |
| 2 |
Praxis Precision Medicines
PRAX
|
+$7.99M |
| 3 |
Insmed
INSM
|
+$5.2M |
| 4 |
Axsome Therapeutics
AXSM
|
+$5.05M |
| 5 |
WHWK
Whitehawk Therapeutics
WHWK
|
+$4.97M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.69% |
| 2 | Miscellaneous | 6.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TERN
1
DELISTED
Terns Pharmaceuticals
TERN
| $17.8M | 17.2% |
+440,000
| New | +$10.2M |
|
|
2
Praxis Precision Medicines
PRAX
$9.63B
| $12.6M | 12.24% |
+42,900
| New | +$7.99M |
|
|
3
Axsome Therapeutics
AXSM
$10.4B
| $6.61M | 6.4% |
+36,200
| New | +$5.05M |
|
4
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
| $5.27M | 5.1% |
+31,000
| New | +$4.75M |
|
|
WHWK
5
Whitehawk Therapeutics
WHWK
$263M
| $5.24M | 5.07% |
+2,165,997
| New | +$4.97M |
|
6
Trevi Therapeutics
TRVI
$2.39B
| $5.18M | 5.02% |
+414,000
| New | +$4.78M |
|
|
7
Insmed
INSM
$25.9B
| $4.96M | 4.8% |
+28,497
| New | +$5.2M |
|
8
Protagonist Therapeutics
PTGX
$9.34B
| $4.63M | 4.48% |
+53,000
| New | +$4.34M |
|
9
Disc Medicine
IRON
$3.07B
| $4.63M | 4.48% |
+58,250
| New | +$4.92M |
|
|
MBX
10
MBX Biosciences
MBX
$3.03B
| $3.83M | 3.71% |
+121,524
| New | +$2.95M |
|
11
Savara
SVRA
$1.08B
| $3.65M | 3.53% |
+605,280
| New | +$2.96M |
|
12
Travere Therapeutics
TVTX
$6.19B
| $3.48M | 3.36% |
+91,000
| New | +$2.96M |
|
13
Edgewise Therapeutics
EWTX
$4.64B
| $3.3M | 3.19% |
+133,000
| New | +$2.67M |
|
|
14
Jazz Pharmaceuticals
JAZZ
$15.9B
| $2.98M | 2.88% |
+17,500
| New | +$2.68M |
|
|
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
| $2.76M | 2.67% |
+59,700
| New | +$3.27M |
|
16
United Therapeutics
UTHR
$22.1B
| $2.31M | 2.24% |
+4,750
| New | +$2.21M |
|
17
Achieve Life Sciences
ACHV
$834M
| $2.3M | 2.22% |
+462,355
| New | +$2.02M |
|
18
Revolution Medicines
RVMD
$44.6B
| $2.19M | 2.12% |
+27,500
| New | +$1.8M |
|
19
Scholar Rock
SRRK
$7.04B
| $1.98M | 1.92% |
+45,000
| New | +$1.69M |
|
20
Vera Therapeutics
VERA
$2.46B
| $1.66M | 1.6% |
+32,700
| New | +$1.16M |
|
21
CALL
Fulcrum Therapeutics
FULC
$294M
| $1.25M | 1.21% |
+110,900
| New | +$1.13M |
|
22
Immix Biopharma
IMMX
$992M
| $1.21M | 1.17% |
+230,423
| New | +$948K |
|
23
Nektar Therapeutics
NKTR
$2.48B
| $1.14M | 1.1% |
+26,900
| New | +$1.51M |
|
24
Cabaletta Bio
CABA
$529M
| $1.11M | 1.07% |
+505,431
| New | +$1.25M |
|
|
25
Fulcrum Therapeutics
FULC
$294M
| $566K | 0.55% |
+50,000
| New | +$509K |
|
Similar funds
RC
TH
WFA
SB
II
FEM
SCM
VSCP
KVP Capital Advisors's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for KVP Capital Advisors, which disclosed 27 positions worth $103M. Its ten largest holdings account for 68% of the portfolio.
Its largest position is Terns Pharmaceuticals: 440,000 shares worth $17.8M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, followed by Miscellaneous.
- KVP Capital Advisors's largest Q4 2025 buy was Terns Pharmaceuticals: 440,000 shares worth $17.8M.
- KVP Capital Advisors's ten largest holdings make up 68% of its $103M portfolio in Q4 2025.
- KVP Capital Advisors disclosed 27 positions in Q4 2025, its first 13F filing on record.
Based on KVP Capital Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.